A new JAMA communication on vaping raises a wider question: how should clinicians, policymakers and public-health professionals talk about nicotine pouches with adults who smoke?
How health professionals communicate about nicotine matters.
For years, public discussion of nicotine has often struggled to distinguish the harms caused by smoking from the effects of nicotine itself, or to explain that different nicotine products can carry very different risk profiles.
A new Special Communication published in JAMA brings this problem into the clinical setting.
Writing on nicotine e-cigarettes and smoking cessation, researchers from the Society for Research on Nicotine and Tobacco’s Treatment Research Network Harm Reduction Workgroup argue that clinicians should integrate e-cigarettes into patient-centred discussions about evidence-based smoking-cessation options. The authors point both to evidence supporting vaping for cessation and to persistent misperceptions about relative harm, including among clinicians.
For GINN, the paper raises a related question.
What would an appropriately evidence-based conversation look like if the product under discussion were nicotine pouches?
The answer cannot simply be copied from vaping. The evidence bases are different. But the underlying communication principle, giving adults accurate information about relative risk, benefits, uncertainties and alternatives, is highly relevant.
JAMA Puts Communication at the Centre
The JAMA Special Communication makes one overarching recommendation: clinicians should integrate nicotine e-cigarettes into conversations about the risks and benefits of evidence-based pharmacological smoking-cessation treatments.
This involves more than simply telling patients whether they should or should not vape.
The authors advocate patient-centred shared decision-making, addressing misconceptions about relative harm and providing practical information that allows adults who smoke to understand their options.
That is significant because communication itself can influence behaviour.
If an adult who smokes believes every nicotine-containing product is as harmful as cigarettes, there may be little perceived reason to move away from combustion. Conversely, presenting a lower-risk product as harmless would also fail to communicate the evidence accurately.
Good risk communication therefore requires something more nuanced: products can be substantially different in risk without being risk-free.
This principle deserves consideration beyond vaping.
What If the Conversation Were About Nicotine Pouches?
Nicotine pouches are increasingly visible in the US and internationally. They contain nicotine but no tobacco leaf and are placed between the lip and gum, allowing nicotine to be absorbed through the oral mucosa.
Their lack of combustion immediately distinguishes them from cigarettes. They also avoid inhalation.
A separate JAMA Patient Page published on the same day as the e-cigarette communication provides a useful indication of how that distinction can be communicated without overstating the evidence.
It notes that nicotine pouches can contain lower levels of some carcinogens than cigarettes and traditional smokeless tobacco products. Compared with e-cigarettes, they avoid inhalation of flavourings, heavy metals, heated carrier liquids and other aerosol byproducts, although pouch use may produce oral adverse effects. Importantly, the long-term effects of nicotine pouch use remain uncertain.
That combination, lower exposure to many hazards alongside clearly stated uncertainty and potential harms, is precisely the type of communication a risk-proportionate framework requires.
But Pouches and Vapes Are Not Interchangeable
This is where caution becomes particularly important.
The JAMA Special Communication reports that nicotine e-cigarettes have been shown to be more effective for smoking cessation than US FDA-approved nicotine replacement therapies. That evidence underpins the authors’ recommendation that clinicians include vaping when discussing cessation options.
GINN should not simply transfer that conclusion to nicotine pouches.
The evidence is not there yet.
JAMA’s recent overview of nicotine pouches states that pouches have not been demonstrated to improve smoking-cessation outcomes. However, it also notes that adults who completely switch from cigarettes to pouches reduce their exposure to many smoking-related carcinogens.
That creates an important distinction between two questions:
Can nicotine pouches reduce exposure when they completely replace smoking?
Current evidence provides a basis for discussing that possibility.
Have nicotine pouches been established as effective smoking-cessation treatments?
At present, that conclusion would go beyond the evidence.
Good communication needs to preserve both facts.
Complete Switching Matters
The distinction between complete switching and continued smoking is also important.
The potential harm-reduction benefit of a smoke-free product depends substantially on whether it displaces cigarette consumption. Continuing to smoke while adding another nicotine product may not produce the same reduction in exposure as completely moving away from combustible cigarettes.
That should be part of any responsible conversation with adults who smoke.
Rather than communicating that nicotine pouches are simply “safe” or “unsafe,” a more useful discussion would distinguish between continued smoking, dual use, complete switching and nicotine abstinence.
These are different behaviours with different implications.
For an adult who does not currently use nicotine, avoiding initiation remains the appropriate message. For an adult who smokes, however, information about the relative risks of continuing to smoke versus completely switching to a non-combustible product can be relevant to informed decision-making.
FDA Developments Make Accurate Communication More Relevant
Recent US regulatory developments make this discussion especially timely.
In July 2026, the US Food and Drug Administration authorised 20 ZYN nicotine pouch products to carry a modified-risk claim. The authorised communication states that using the products instead of cigarettes reduces the risk of several smoking-related diseases.
According to the FDA assessment reported by JAMA, regulators considered the relative risks to people who use tobacco, consumers’ understanding of the claim and potential youth risks before determining that the claim was accurate, understandable and expected to benefit population health.
This does not mean nicotine pouches are harmless, nor does modified-risk authorisation turn them into approved smoking-cessation medicines.
It does demonstrate something important about communication: regulators can distinguish between acknowledging lower risk relative to cigarettes and claiming that a product is safe or therapeutically proven.
That distinction should be central to nicotine policy.
Misperceptions Can Have Consequences
One of the most important observations in the JAMA e-cigarette communication is that misconceptions about relative harm remain common, including among clinicians.
This matters because inaccurate risk perceptions can undermine informed choices.
Public-health communication understandably emphasises that nicotine products are not harmless and that young people and non-users should not initiate use. But those messages need not require presenting every nicotine product as equivalent to cigarettes.
The challenge is communicating two ideas simultaneously:
Nicotine products can involve addiction and health risks, and should not be used by people who otherwise would not use nicotine.
At the same time, combustible cigarettes occupy a fundamentally different position because burning tobacco creates the toxic smoke responsible for much of smoking-related disease.
Effective communication should be capable of holding both propositions at once.
Youth Protection Must Remain Part of the Conversation
Risk-proportionate communication is not a case for indiscriminate promotion.
Nicotine pouches raise legitimate concerns around youth access, flavours, marketing and accidental exposure. JAMA notes increasing pouch use among young people and highlights accidental nicotine ingestion among young children as an area requiring attention.
Those concerns require appropriate safeguards.
Regulation can restrict sales to adults, establish product standards, address marketing practices, require appropriate warnings and packaging, and monitor youth uptake.
But youth protection and accurate adult risk communication should not automatically be treated as mutually exclusive goals.
Policymakers should be able to protect people who should not use nicotine while still providing accurate information to adults who already smoke.
What Could a Pouch Conversation Actually Say?
If the principles behind the JAMA communication were adapted cautiously to nicotine pouches, the conversation would not begin with “nicotine pouches will help you quit smoking.”
The evidence currently does not justify that statement.
Instead, an evidence-aligned discussion might explain that cigarettes expose users to toxic products of combustion; nicotine pouches eliminate combustion and inhalation; they are not risk-free and can cause nicotine dependence and oral adverse effects; their long-term health effects require further study; and evidence has not yet established them as smoking-cessation treatments.
For adults who nevertheless choose pouches instead of cigarettes, the distinction between complete substitution and continued smoking should also be made clear.
That is not product promotion.
It is risk communication.
From Product Warnings to Informed Communication
The wider lesson from the new JAMA paper is therefore not that every alternative nicotine product should receive the same clinical recommendation.
It is that nicotine communication should reflect what the evidence actually says about each product.
For vaping, there is now a substantial cessation evidence base, which led the JAMA authors to recommend its inclusion in clinician-patient discussions. For nicotine pouches, evidence about cessation remains much less developed, and important questions about long-term effects remain unresolved.
Those differences should be communicated rather than flattened.
For GINN, this points toward a broader principle for good nicotine governance: communication should be proportionate to evidence as well as risk.
Adults who smoke should receive accurate information about the risks of continued smoking, the characteristics of smoke-free alternatives, what is known about relative exposure, and what remains uncertain. Young people and non-users should receive a clear message not to initiate nicotine use.
Neither exaggerating the evidence for nicotine pouches nor ignoring potentially meaningful differences from cigarettes serves informed decision-making.
As nicotine markets continue to evolve, policymakers and health professionals will increasingly need to communicate in shades of risk rather than categories of “safe” and “dangerous.”
The JAMA recommendations for vaping offer one model for how those conversations can become more evidence-based.
For nicotine pouches, the task now is to develop the evidence necessary to make those conversations equally useful.
